With Apollo Endosurgery acquisition, Boston Scientific dives into the obesity treatment market

The landscape of obesity treatment is quickly changing — and with its acquisition this week of Apollo Endosurgery, medical device maker Boston Scientific is again shaking up the space.

“We’ve been calling it a measured entry into the bariatric space,” said Brian Dunkin, who oversees the medical affairs of Boston Scientific’s endoscopy division. “We want to get our experience using a technology that has clinical data to support its use.”

For decades, Boston Scientific’s core focus has been on minimally invasive surgery; it sells devices to treat cardiological, urological, and neurological disease. In 2022, nearly one-fifth of the company’s sales were from devices used in endoscopies, a less-invasive procedure used to look inside the body.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In